Table 1.
Clinicopathologic features and Smad2/3/L/C phosphorylation in liver specimens from patients with NASH.
| No. | Age | Sex | AST | ALT | PLT | FiB4 | T-Bil | ALB | PT | F Stage | NI Grade | pSmad3L Staining | pSmad3C Staining | Folluw-up Period | Time to HCC * | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No HCC | 1 | 27 | M | 145 | 319 | 25.1 | 0.87 | 0.9 | 5.1 | 118 | 1 | 1 | 1 | 4 | 12 | |
| 2 | 29 | F | 150 | 248 | 28.0 | 0.99 | 0.7 | 4.3 | 75 | 1 | 1 | 1 | 4 | 12 | ||
| 3 | 38 | M | 59 | 178 | 21.1 | 0.8 | 0.8 | 4.9 | 101 | 1 | 1 | 0 | 4 | 10 | ||
| 4 | 60 | F | 90 | 118 | 26.3 | 1.89 | 0.5 | 4.0 | 102 | 1 | 1 | 1 | 3 | 11 | ||
| 5 | 63 | F | 38 | 43 | 28.4 | 1.29 | 0.5 | 4.9 | 110 | 1 | 1 | 0 | 4 | 15 | ||
| 6 | 68 | F | 84 | 82 | 28.3 | 2.23 | 1.1 | 4.4 | 1 | 1 | 0 | 2 | 13 | |||
| 7 | 72 | F | 49 | 45 | 20.1 | 2.62 | 0.6 | 4.2 | 127 | 1 | 1 | 0 | 2 | 13 | ||
| 8 | 70 | M | 168 | 214 | 16.9 | 4.76 | 1.2 | 4.4 | 74 | 1 | 2 | 2 | 4 | 11 | ||
| 9 | 44 | M | 93 | 169 | 23.9 | 1.32 | 1.4 | 4.5 | 118 | 2 | 1 | 2 | 4 | 13 | ||
| 10 | 45 | F | 84 | 145 | 23.1 | 1.36 | 0.7 | 4.9 | 119 | 2 | 1 | 1 | 3 | 10 | ||
| 11 | 66 | F | 29 | 29 | 19.2 | 1.85 | 0.5 | 4.2 | 115 | 2 | 1 | 0 | 4 | 13 | ||
| 12 | 65 | M | 98 | 35 | 19.3 | 5.58 | 0.4 | 4 | 88 | 2 | 2 | 3 | 4 | 11 | ||
| 13 | 46 | M | 27 | 14 | 11.3 | 2.94 | 0.8 | 3.9 | 88 | 3 | 1 | 1 | 3 | 11 | ||
| 14 | 54 | M | 40 | 86 | 21 | 1.11 | 1.1 | 4.4 | 89 | 3 | 2 | 0 | 3 | 11 | ||
| 15 | 56 | F | 155 | 192 | 12.5 | 5.01 | 1.1 | 4.3 | 3 | 2 | 1 | 3 | 12 | |||
| 16 | 57 | F | 30 | 24 | 16.9 | 2.07 | 0.7 | 4.3 | 107 | 3 | 2 | 0 | 3 | 10 | ||
| 17 | 54 | F | 80 | 99 | 12.8 | 3.39 | 1.2 | 4.4 | 101 | 4 | 2 | 0 | 2 | 13 | ||
| HCC | 18 | 50 | M | 51 | 70 | 9.1 | 3.35 | 1.2 | 4 | 38 | 2 | 1 | 4 | 1 | 8.25 | |
| 19 | 60 | M | 19 | 14 | 17.3 | 1.76 | 0.4 | 4.7 | 126 | 2 | 1 | 3 | 2 | 0 | ||
| 20 | 72 | M | 53 | 9.8 | 6.06 | 0.8 | 3.8 | 84 | 3 | 1 | 3 | 4 | 3.92 | |||
| 21 | 75 | M | 44 | 38 | 15.8 | 3.39 | 0.9 | 4 | 92 | 3 | 1 | 4 | 2 | 0 | ||
| 22 | 78 | F | 31 | 21 | 4.3 | 12.27 | 1.7 | 3.3 | 64 | 3 | 1 | 2 | 2 | 1.92 | ||
| 23 | 69 | M | 50 | 39 | 9.1 | 6.07 | 1.3 | 3.8 | 83 | 3 | 2 | 4 | 2 | 1.83 | ||
| 24 | 58 | M | 64 | 61 | 5 | 9.51 | 2.2 | 4 | 67 | 4 | 1 | 3 | 2 | 0 | ||
| 25 | 73 | M | 64 | 72 | 8.4 | 6.55 | 1 | 3.1 | 44 | 4 | 1 | 3 | 1 | 0 | ||
| 26 | 71 | M | 129 | 73 | 9.9 | 10.83 | 2.9 | 3.7 | 72 | 4 | 2 | 4 | 1 | 0 | ||
| 27 | 76 | F | 59 | 29 | 8.4 | 9.91 | 1.2 | 3.2 | 77 | 4 | 2 | 2 | 2 | 3.92 | ||
| 28 | 80 | F | 28 | 16 | 4.4 | 12.73 | 1.2 | 3.1 | 64 | 4 | 2 | 4 | 2 | 0 | ||
| 29 | 69 | F | 48 | 23 | 7 | 9.87 | 2.4 | 2.6 | 50 | 4 | 3 | 4 | 2 | 3.83 | ||
| 30 | 75 | M | 33 | 14 | 10.4 | 6.36 | 0.9 | 3.6 | 87 | 4 | 3 | 4 | 2 | 0 |
* 0 indicates that HCC had already occurred when liver biopsy was performed. NASH, nonalcoholic steatohepatitis. HCC, hepatocellular carcinoma. F, fibrosis. NI, necroinflammatory.